Revenue YoY
+10.41%
Operating Income YoY
+743.38%
Net Income YoY
+538.70%
Net Margin Δ
+4431 bps
Net income bridge for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: $5.33B+538.70%
Profit bridge breakdown for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | −$988.90M | — |
| Revenue | $1.16B | +21.7% |
| Cost of Revenue | −$130.20M | -2.4% |
| Operating Expenses | $4.49B | +84.3% |
| Other Income / Expense | −$52.20M | -1.0% |
| Income Tax | −$138.70M | -2.6% |
| Net Income | $4.34B | — |
- Prior Net Income−$988.90M
- Revenue$1.16B
- Cost of Revenue−$130.20M
- Operating Expenses$4.49B
- Other Income / Expense−$52.20M
- Income Tax−$138.70M
- Net Income$4.34B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement